D Y Patil College of Engineering, Akurdi, Pune-44
Department of Computer Engineering, Kuran
Name: Omkar Dnyaneshwar Narveer Roll No: MTECH242506
Class: MTECH First Year Academic Year: 2024-25
Subject: Research Methodology Course Code: RMD24O9L01
Semester: I
________________________________________________________________
Tutorial 4: Analyse a case study on ethical dilemmas in research and propose
solutions.
Case Study: Ethical Dilemmas in Medical Research
Background
A research team at a prestigious medical university is conducting a clinical trial
to test a new drug aimed at treating a specific type of cancer. The trial is double-
blind, randomized, and involves a placebo group. The researchers recruit patients
who have been diagnosed with this type of cancer, and the study is designed to
last for 12 months. The drug has shown promising results in preliminary animal
trials and small-scale human studies.
However, during the course of the trial, a subset of patients experiences adverse
side effects not anticipated by the researchers. Some of the patients develop
severe, life-threatening complications that were not observed in the pre-clinical
studies. The research team is faced with the ethical dilemma of whether they
should:
Continue the trial as planned, to maintain the integrity of the research design, or
Disclose the adverse effects immediately to all participants, potentially
jeopardizing the entire trial, or
Modify the trial to provide early access to the drug for participants who have
suffered complications, which could alter the study's outcomes.
D Y Patil College of Engineering, Akurdi
Ethical Dilemmas in the Case
Informed Consent and Participant Welfare:
Issue: The patients involved in the study were not fully informed about the
possibility of severe adverse effects, as they were only told about the risks
observed in the earlier trials, which did not include the severe complications.
Ethical Dilemma: Is it ethical to continue withholding information about the new
adverse effects from the patients who are still participating in the study, as they
have a right to know about the risks associated with the drug?
Clinical Integrity vs. Patient Safety:
Issue: Continuing the study as planned would preserve the integrity of the trial
design and ensure valid results. However, the health and safety of the participants
are now at risk due to the unexpected side effects.
Ethical Dilemma: Should the researchers prioritize the scientific integrity of the
study, or should patient safety be the primary concern, even if this means altering
or halting the study?
Placebo Group and Potential Harm:
Issue: Participants in the placebo group are not receiving any treatment, and the
researchers are now aware that the drug can have harmful side effects.
Ethical Dilemma: Should the researchers offer treatment to those in the placebo
group if they are at risk of adverse effects, even though this would introduce bias
into the trial's results?
Conflict of Interest:
Issue: The research team is under pressure from the pharmaceutical company
funding the trial, which stands to gain financially from the success of the drug.
There may be a conflict of interest influencing the decisions of the researchers.
Ethical Dilemma: How can the researchers ensure that their decision-making is
not influenced by financial or career motivations, but rather by the ethical
responsibility they have to their patients and the scientific community?
D Y Patil College of Engineering, Akurdi
Proposed Solutions
1. Ensure Transparent and Ongoing Informed Consent
Solution: The researchers should immediately disclose the new adverse side
effects to all current participants and obtain re-consent. Even though the initial
consent process mentioned only the known risks, the ethical duty to protect
patients’ welfare supersedes the need to maintain study blinding.
Rationale: Ethical guidelines, such as those outlined in the Declaration of
Helsinki, emphasize that participants must be fully informed of risks and that they
have the right to withdraw from the study at any time without penalty. Providing
them with updated information ensures their right to make an informed decision
about their continued participation.
2. Prioritize Patient Safety Over Research Integrity
Solution: Given the severity of the adverse effects, the research team should halt
the trial temporarily to assess the risks and reassess the safety of the drug.
Continuing the trial without this assessment could result in unnecessary harm to
the participants.
Rationale: Ethical research must balance the goals of scientific discovery with
the welfare of human participants. The risk of harm to patients outweighs the
importance of completing the trial as originally designed. Modifying the trial
protocol to ensure patient safety and re-evaluating the drug’s potential risks is the
ethical course of action.
3. Offer Access to Treatment for Placebo Group
Solution: The researchers should offer the treatment to participants in the placebo
group, particularly those who are experiencing severe symptoms of the disease.
It would be unethical to withhold a potentially beneficial treatment from these
patients when the adverse effects of the drug are known and the study no longer
justifies the placebo control.
Rationale: The ethical principle of justice dictates that participants should not be
deprived of a potential benefit, especially when they are suffering from life-
threatening conditions. Offering the drug to the placebo group would not only
mitigate harm but also allow the researchers to gain additional insights into the
drug’s effects under real-world conditions.
4. Address Conflict of Interest and Ensure Independent Oversight
Solution: To avoid undue influence from the pharmaceutical company, the
research team should ensure that independent ethics committees or data safety
D Y Patil College of Engineering, Akurdi
monitoring boards (DSMBs) are overseeing the trial. These external bodies can
help guide decisions about whether to continue or modify the trial, providing
objective oversight free from external pressures.
Rationale: A clear and transparent process of ethical review is crucial when
conflicts of interest exist. Independent oversight ensures that decisions are made
in the best interests of the participants and the integrity of the research.
5. Provide Post-Trial Access to Treatment
Solution: If the drug continues to show promise but with some risks, the
researchers should work with the pharmaceutical company to establish a
compassionate use program. This would allow participants who experienced
adverse effects to continue receiving treatment outside of the clinical trial if they
wish to do so, after proper counselling.
Rationale: Compassionate use programs are ethically appropriate when there are
no other treatment options available for patients. This ensures that the patients
who participated in the study and experienced adverse effects are not left without
options after the trial ends.
Conclusion
In conducting medical research, ethical dilemmas often arise between advancing
scientific knowledge and ensuring participant welfare. In this case study, the
primary ethical issues are informed consent, patient safety, and the integrity of
the clinical trial. The proposed solutions emphasize transparency, patient-
cantered decision-making, and ensuring independent oversight. By prioritizing
patient safety, providing adequate information, and minimizing conflicts of
interest, the research team can ensure that the study is conducted ethically,
protecting the participants while still contributing valuable knowledge to the
medical community.
D Y Patil College of Engineering, Akurdi